High density lipoproteins as a target to reduce the risk of cardiovascular disease: What is the evidence?

Presented by

Professor Philip Barter
Conjoint Professor of Medicine, UNSW
President, International Atherosclerosis Society
Director Emeritus, The Heart Research Institute

11:00 am to 12:00pm, Wednesday 6 August 2014

Level 4 Seminar Space, UNSW Lowy Cancer Research Centre,
UNSW Kensington Campus
corner High and Botany Sts (Map reference C25)

Philip Barter, MBBS, PhD, FRACP, has held positions in research institutes and universities in Australia and the US, including a 10 year term as Director of The Heart Research Institute in Sydney; he is currently based at UNSW where he holds a position as Conjoint Professor of Medicine. He is the current President of the International Atherosclerosis Society. He was the 2011 recipient of the Anitschkow Award of the European Atherosclerosis Society and the 2013 recipient of the Australian Heart Foundation Medal for Lifetime Contribution to Cardiovascular Research. His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins. His clinical research involves participation in clinical trials of lipid-lowering agents. He has been a member of the executive of the steering committees of seven major international clinical outcome trials (two as Chairman) investigating the effects of lipid modifying agents on cardiovascular disease. He has published more than 350 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function and relationship to atherosclerosis. He has also written handbooks on HDL and CETP inhibitors.

Kindly supported by